Home › Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress
 

Keywords :   


Merck Announces Longer-Term Follow-Up of Overall Survival Data for KEYTRUDA (pembrolizumab) in Patients with Advanced Melanoma from KEYNOTE-002 Presented at ESMO 2016 Congress

2016-10-08 14:45:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Data Comparing KEYTRUDA to Chemotherapy Shows Continued Benefit with Follow-Up Beyond 2.5 Years in Patients with Ipilimumab-Refractory Advanced Melanoma KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from the final overall survival (OS) analysis from the KEYNOTE-002 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, compared to investigator-choice chemotherapy with a crossover to KEYTRUDA design, in patients with ipilimumab-refractory advanced melanoma. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: data advanced presented patients

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.05Is Zimbabwe zigzagging into further currency chaos?
05.05Why mortgage rates are going up, not down
04.05This Week in Agribusiness, May 4, 2024
04.05Weekly Recap: Sherwin-Williams, BASF, Abrafati Top This Weeks Stories
03.05'Garden floods show need to work with nature'
03.05Worst-ever job interviews: 'We had to crawl and moo'
03.05Have the wheels come off for Tesla?
03.05BW Converting focuses on time, energy and cost savings at INFOFLEX
More »